Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview Of Cell Separation And Isolation01:20

Overview Of Cell Separation And Isolation

7.7K
Cell separation was first achieved in 1964 by S. H. Seal, who separated large tumor cells from the smaller blood cells using filtration. Two years later, Pohl and Hawk performed experiments on how cells respond differently to a nonuniform electric field based on the cell type. Such observations were the inception of cell separation methods, which allow isolating a single cell type from a heterogeneous sample.
7.7K
Cell Culture01:21

Cell Culture

23.0K
Most vertebrate cells grow in vitro attached to a substrate as a monolayer, called adherent cultures. The flasks and plates used to grow cells are chemically treated to facilitate cell attachment. However, a few cell types, such as hematopoietic cells, can grow in a suspension. In contrast to adherent cultures, suspension cultures can grow in non-treated cultureware using magnetic stirrers or spinner flasks to agitate the culture media
23.0K
Cell Lines01:16

Cell Lines

10.5K
A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
10.5K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

2.2K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.2K
Stem Cell Culture01:17

Stem Cell Culture

6.2K
Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Clinical translation and commercialisation of advanced therapy medicinal products, volume II.

Frontiers in bioengineering and biotechnology·2026
Same author

Editorial: Clinical Translation and Commercialisation of Advanced Therapy Medicinal Products.

Frontiers in bioengineering and biotechnology·2020
Same author

TOX: a rediscovered master molecular actor to enhance immuno-oncology interventions.

Cellular & molecular immunology·2019
Same author

Recent Progress in European Advanced Therapy Medicinal Products and Beyond.

Frontiers in bioengineering and biotechnology·2018
Same author

Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View.

Tissue engineering. Part B, Reviews·2016
Same author

Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.

Tissue engineering. Part B, Reviews·2015
Same journal

Industry updates in advanced therapy medicinal products and regenerative medicine - May 2026.

Regenerative medicine·2026
Same journal

Ethical, legal, and social issues associated with human fetal tissue research in Japan.

Regenerative medicine·2026
Same journal

The future of hematopoietic stem cell and stem cell gene therapy for metabolic diseases.

Regenerative medicine·2026
Same journal

Exploring gene therapy for developmental and epileptic encephalopathies (DEEs): possibilities or promises?

Regenerative medicine·2026
Same journal

Industry updates in advanced therapy medicinal products and regenerative medicine - April 2026.

Regenerative medicine·2026
Same journal

Optimizing strategies in tendon tissue engineering through effective scaffold design: overview of recent advancements.

Regenerative medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 16, 2026

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

5.1K

Methods and practices to diversify cell-based products.

Alain A Vertès1

  • 1London Business School, UK & NxR Biotechnologies GmbH, Basel, Switzerland.

Regenerative Medicine
|December 16, 2017
PubMed
Summary
This summary is machine-generated.

This study introduces an innovation framework for medicinal signaling cell (MSC) therapies to enhance clinical benefits and market access. It explores product delineation through composition, formulation, manufacturing, delivery, and molecular engineering for advanced cell-based treatments.

Keywords:
adult stem cellscytotherapyinnovation S-curveinnovation chunkmarket accessmedicinal signaling cellsmesenchymal stem cellsmesenchymal stromal cellsproduct delineationproduct differentiationproduct versioning

More Related Videos

Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

9.8K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.8K

Related Experiment Videos

Last Updated: Feb 16, 2026

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
09:44

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

5.1K
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

9.8K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.8K

Area of Science:

  • Regenerative Medicine
  • Cell-based Therapies
  • Biotechnology

Background:

  • Medicinal signaling cell (MSC)-based products are emerging treatments for diverse conditions like cardiometabolic diseases, inflammation, and oncology.
  • Current MSC therapies often involve minimally manipulated, plastic-adherent, ex vivo expanded allogeneic MSCs.
  • Product delineation is crucial for maximizing clinical benefits and market access for these advanced therapies.

Purpose of the Study:

  • To present an innovation framework for delineating MSC-based products.
  • To explore various dimensions of innovation in cell-based therapies.
  • To guide the development of next-generation MSC therapies.

Main Methods:

  • The study outlines an innovation framework encompassing multiple dimensions.
  • Dimensions include composition-of-matter (e.g., cell surface markers), formulation (e.g., cell dose, preservation), and manufacturing (e.g., secretome adaptation).
  • Additional dimensions include mode of delivery, delivery devices, molecular engineering, and biomarkers.

Main Results:

  • The proposed framework enables comprehensive product delineation for MSC-based therapies.
  • It identifies key areas for innovation to improve therapeutic outcomes.
  • The framework facilitates the development of novel cell-based products with enhanced efficacy and accessibility.

Conclusions:

  • The presented innovation framework provides a roadmap for advancing MSC-based products.
  • This approach is critical for maximizing the clinical and commercial potential of cell therapies.
  • The framework's principles are broadly applicable to all cell-based therapeutic innovations.